ICON Blockchain Network Launches ICONFi, A New Crypto Staking-and-Earn Service Built for Beginners

ICONFi makes it easier than ever to grow your digital asset investments starting with ICX, BTC, ETH, and USDT

Singapore, Nov. 23, 2020 (GLOBE NEWSWIRE) — (via Blockchain Wire) – The ICON blockchain network, one of the world’s largest decentralized networks, today announced ICONFi (https://icon-fi.com/), a new cryptocurrency staking-and-earn service built for beginners. ICONFi introduces easy-to-use features like one-click staking and automated re-staking to make it easier than ever for people to grow their digital asset investments. The service supports ICX, BTC, ETH, and USDT, with plans to add new cryptocurrencies in the future based on demand. 

For many crypto users, decentralized wallets are challenging to operate properly, resulting in the loss of private keys or passwords and ultimately the loss of funds. This can deter people from the crypto ecosystem altogether. ICONFi was designed to solve this problem with a simple, secure, low-friction service for helping users stake and grow their digital asset investments. ICONFi is a hassle-free, all-in-one wallet that integrates services designed to grow digital assets of all kinds, allowing beginners to get involved with crypto yield products and services. 

“Our goal with ICONFi is to create a more inclusive and diverse ICON community by bringing clear benefits to crypto beginners,” said Min Kim, ICON Project Founder. “We believe ICONFi can be the gateway to other DeFi products like decentralized wallets, as well as an entry point for the ICON ecosystem and blockchain technology as a whole.” 

Key features of ICONFi include: 

  1. One-Click Staking for Rewards. This feature simplifies the staking process, and helps ICX holders vote more easily. 
  2. Auto ICX Claiming and Re-Staking for More Rewards. Many users are frustrated with the process of manually claiming and re-staking their digital assets. This highly requested feature automates the process to accelerate staking, and helps to further secure the ICON network. 
  3. Staking and Earn Support for Additional Digital Assets. ICONFi will support savings products for digital assets outside of the network, starting with BTC, ETH, and USDT. Support for additional cryptocurrencies will be based on community interest. 

ICONFi is led by Min Kim, Founder of the ICON Project, and Sean Kim, a seasoned expert in financial products and underlying trading systems. The ICONFi team currently consists of fifteen (15) members with extensive background in quantitative trading, asset management, business operations and blockchain technology. 

The service will open in December 2020. At launch, ICONFi will offer a 20% APY fixed-term product on select crypto asset deposits. 

ABOUT ICONFi 

ICONFi (https://icon-fi.com/), a cryptocurrency staking and earn service. ICONFi provides a simple solution for staking ICON’s cryptocurrency, ICX, and allows users to earn yields on other assets including BTC, ETH, and USDT. ICONFi helps crypto newcomers grow their investments with a simple, secure, low-friction service.  ICONFi’s features include one-click staking for rewards and automated claiming and re-staking. 

Attachments



Company Contact: [email protected] 

Media Contact: Transform Group, [email protected] 

Myovant Sciences to Present at Upcoming December Investor Conferences

BASEL, Switzerland, Nov. 23, 2020 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences:

  • Evercore ISI 3

    rd

    Annual HealthCONx Virtual Conference on December 1, 2020 at 4:45 p.m. Eastern time. Lynn Seely, M.D., chief executive officer of Myovant Sciences, Inc., and Frank Karbe, president and chief financial officer of Myovant Sciences, Inc., will participate in a webcast presentation. Management will also participate in virtual one-on-one investor meetings on December 1.

  • Piper Sandler 32

    nd

    Annual Virtual Healthcare Conference. A pre-recorded presentation by Dr. Seely will be available at 10 a.m. Eastern time today on the investor relations page of Myovant’s website, investors.myovant.com. Management will participate in virtual one-on-one investor meetings on December 3, 2020.

The presentations will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

About Myovant Sciences

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix monotherapy tablet (120 mg) is under regulatory review in the U.S. for men with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:

Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
[email protected]

Media Contact:

Albert Liao
Director, Corporate Communications
Myovant Sciences, Inc.
[email protected]



Amicus Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference

CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference being held virtually on Tuesday, December 1, 2020 at 2:15 p.m. E.T.

A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.


About Amicus Therapeutics


Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.

CONTACT:

Investors:

Amicus Therapeutics
Andrew Faughnan
Director, Investor Relations
[email protected]
(609) 662-3809

Media:

Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
[email protected]
(609) 662-5079

FOLD–G



Announcing Intellicentrics Newly Created “5th Ring Advisory Board”

Announcing Intellicentrics Newly Created “5th Ring Advisory Board”

Accelerating Open, Early Stage Technology Collaboration with the Goal of Democratizing Access to High-Quality Healthcare

DALLAS–(BUSINESS WIRE)–
IntelliCentrics (6819.HK), creator of SEC³URE Ethos, SEC³URE Passport, Link & GO! and BioBytes™ serving North America, the United Kingdom and China, all on an integrated, end-to-end technology platform, announced that IntelliCentrics’ “5th Ring Advisory Board” has been created and will be led by IntelliCentrics Chief Innovation Officer (CIO) and long-term executive David Taylor.

“I was so fascinated by IntelliCentrics’ vision to improve healthcare by integrating love from family and friends with the medical sciences; that I was delighted to be allowed early access to everything they were working on,” said Dr. Naseer Ahmad of Manchester University NHS Foundation Trust, one of the largest NHS Trusts in the UK. “What I saw was amazing. By integrating telehealth, personal health records, credentialing, and scheduling with the ability to include family and friends in the care and wellness process, IntelliCentrics has created an exciting and comprehensive health tech innovation. A crucial part for me was how the technology provided everyone from patient to the medical doctor trusted interactions with freedom from paperwork across the entire continuum of care,” continued Dr. Ahmad.

“Dr. Naseer is a visionary in his own right. We have found including luminaries like Dr. Naz and Dr. Linda Ash-Jackson early in the innovation process allows for deeper and more meaningful collaboration,” said David Taylor, CIO of IntelliCentrics. “IntelliCentrics’ 5th Ring Advisory Board exemplifies our commitment to leveraging our open technology platform and collaborative mindset. Let this be our invitation to the world to join us in our mission to make high-quality healthcare as accessible as a good cup of coffee.”

“I have seen firsthand how IntelliCentrics’ technology increases the quality of care while lowering costs,” said Dr. Linda Ash-Jackson, a retained medical consultant of the company. “With 30+ years of industry experience ranging from private practice to chief medical officer for some of the industry’s most important organizations, I truly believe healthcare is at its best when diverse individuals actively collaborate. So, I am very excited to participate in IntelliCentrics’ 5th Ring Advisory Board because improving access to high-quality care for the millions of people in need is core to my life’s work.”

About Dr. Naseer Ahmad

Dr. Naseer Ahmad has an unconventional background for a highly specialist surgeon. He didn’t speak until he was five years old and then failed all his school exams. However, he has since gone on to be awarded five degrees and lectures internationally on lower limb vascular disease. He jokingly says, he sees the world differently because ‘my brain is wired differently’. He qualified in 2002 from Liverpool and undertook his medical and academic training in Merseyside. He has since overseen a reduction in major amputations of 23% at his institution over a three-year period and is currently the Director of The Manchester Amputation Reduction Strategy (The MARS Project). This project is developing a “whole systems” approach to reducing amputations and is working across Public Health, Community, Hospital, Digital and Procurement to develop a harmonized approach to healthcare.

About Dr. Linda Ash-Jackson

Dr. Linda Ash-Jackson, MD brings over thirty years of healthcare delivery and management experience from her positions as Medical Director and Chief Medical Officer at national insurers and managed care companies like CIGNA and Aetna where she served as national medical director responsible for Quality, Credentialing, and Utilization Management. As Chief Medical officer, she was instrumental in providing the administrative and clinical guidance for the development of a managed care system at deNovis in the early 2000s that is the foundation for the managed care system, Health Edge, today. Most recently, she served for almost 15 years as the Chief Medical Officer of Hometown Health in Reno, Nevada, the insurance company wholly owned by Renown Health, the largest integrated delivery system in Northern Nevada.

About IntelliCentrics

With a mission to use trust to make high-quality healthcare as accessible as a good cup of coffee, IntelliCentrics created the SEC³URE Ethos. Built on three core principles – transparency, neutrality, and independence, the SEC³URE Ethos is relied on by more than 11,000 locations of care worldwide to ensure mutual trust between patients, doctors, vendor representatives and healthcare companies. To learn more about the world’s largest trusted healthcare technology platform, visit www.intellicentrics.com. IntelliCentrics is publicly traded on the Stock Exchange of Hong Kong Limited under the stock code 6819.

Hope Runyan

(469) 257-3810

[email protected]

KEYWORDS: Texas China United States United Kingdom North America Asia Pacific Europe

INDUSTRY KEYWORDS: Data Management Health Technology Other Health Software General Health

MEDIA:

Logo
Logo

Enthusiast Gaming Appoints KPMG LLP as New Auditor

TORONTO, Nov. 23, 2020 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX)(OTCQB: ENGMF)(FSE: 2AV), the largest gaming platform in North America, connecting with over 300 million gamers monthly worldwide, today announced that its board of directors has proposed to change its auditors to KPMG LLP (“KPMG”) from MNP LLP (“MNP”), effective at the Company’s next annual general meeting of shareholders.

The change in auditors is part of the Company’s strategy and path towards its anticipated NASDAQ listing, while also ensuring that it is adequately positioned for ongoing rapid growth and evolution.

In accordance with National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”) the Company has filed a Change of Auditor Notice on SEDAR together with letters from each of the new auditor and the former auditor, with each letter confirming agreement with the statements contained in the notice, as applicable. There are no reportable events including disagreements, consultations, or unresolved issues as defined in NI 51-102.

About Enthusiast Gaming

Enthusiast Gaming (TSX: EGLX) (OTCQB: ENGMF)(FSE: 2AV) is building the world’s largest social network of communities for gamers and esports fans that reaches over 300 million gaming enthusiasts on a monthly basis. Already the largest gaming platform in North America and the United Kingdom, the Company’s business is comprised of four main pillars: Esports, Content, Talent and Entertainment. Enthusiast Gaming’s esports division, Luminosity Gaming, is a leading global esports franchise that consists of 7 professional esports teams under ownership and management, including the Vancouver Titans Overwatch team and the Seattle Surge Call of Duty team. Enthusiast’s gaming content division includes 2 of the top 20 gaming media and entertainment video brands with BCC Gaming and Arcade Cloud, reaching more than 50MM unique viewers a month across 9 YouTube pages, 8 Snapchat shows and related Facebook, Instagram and TikTok accounts. Its 100 gaming-related websites include The Sims Resource, Destructoid, and The Escapist. Enthusiast’s talent division works with approximately 500 YouTube creators such as Pokimane, Flamingo, Anomaly, and The Sidemen. Enthusiast’s entertainment business includes Canada’s largest gaming expo, EGLX (eglx.com), and the largest mobile gaming event in Europe, Pocket Gamer Connects (pgconnects.com). For more information on the Company visit enthusiastgaming.com. For more information on Luminosity Gaming visit luminosity.gg.

Forward Looking Statements 

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that Enthusiast anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, comments with respect to strategies, expectations, planned operations and future actions of the Company. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. Forward-looking information is based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of Enthusiast to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors may be based on information currently available to Enthusiast, including information obtained from third-party industry analysts and other third-party sources, and are based on management’s current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement. Trading in the securities of the Company should be considered highly speculative.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contact: 
Eric Bernofsky, Chief Corporate Officer, 416.623.9360
[email protected]

Media Relations – ID Public Relations
[email protected]

IGM Biosciences to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, has participated in a fireside chat in advance of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.

A recording of the fireside chat is now available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations and will be available for 90 days.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
[email protected]



CI Global Asset ManagementAnnounces November 2020 Distributions for CI ETFs

CI Global Asset ManagementAnnounces November 2020 Distributions for CI ETFs

NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

TORONTO–(BUSINESS WIRE)–
CI Global Asset Management (“CI GAM”) today announced the November 2020 cash distributions for certain exchange-traded funds (“ETFs”) as indicated in the table below. Unitholders of record on November 30, 2020 will receive cash distributions payable on December 7, 2020. The ex-dividend date for the distribution is November 27.

Details of the per-unit distribution amounts are as follows:

ETF Name

Ticker

Cash

Distribution

Per Unit ($)

Distribution

Frequency

CI Yield Enhanced Canada Aggregate Bond Index ETF

CAGG

0.117

Monthly

CI Yield Enhanced Canada Short-Term Aggregate Bond Index ETF

CAGS

0.103

Monthly

CI ONE North American Core Plus Bond ETF

ONEB

0.104

Monthly

Further information about the ETFs can be found at www.firstasset.com

About CI Global Asset Management

CI Global Asset Management is one of Canada’s largest investment management companies. It offers a wide range of investment products and services and is on the web at www.ci.com. CI GAM is a subsidiary of CI Financial Corp. (TSX: CIX) (NYSE: CIXX), an independent company offering global asset management and wealth management advisory services with $202.4 billion in total assets as of October 31, 2020.

This communication is intended for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase exchange-traded funds (ETFs) managed by CI Global Asset Managementand is not, and should not be construed as, investment, tax, legal or accounting advice, and should not be relied upon in that regard.

Commissions, management fees and expenses all may be associated with an investment in ETFs. You will usually pay brokerage fees to your dealer if you purchase or sell units of an ETF on recognized Canadian exchanges. If the units are purchased or sold on these Canadian exchanges, investors may pay more than the current net asset value when buying units of the ETF and may receive less than the current net asset value when selling them. Please read the prospectus before investing. Important information about an exchange-traded fund (ETF) is contained in its prospectus. ETFs are not guaranteed; their values change frequently and past performance may not be repeated.

CI Global Asset Management is a registered business name of CI Investments Inc.

©CI Investments Inc. 2020. All rights reserved.

CI Global Asset Management

416-642-1289

1‐877‐642‐1289

www.firstasset.com

Murray Oxby

Vice-President, Corporate Communications

CI Global Asset Management

416-681-3254

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Louisiana Tech University Improves Student Outcomes with Mediasite for Hybrid Learning

Campus holds in-person and online classes; Leaders say recorded lectures improve student success, access to education

MADISON, Wis., Nov. 23, 2020 (GLOBE NEWSWIRE) — The school year looks markedly different this time around for Louisiana Tech University, but campus leaders are confident they have the perfect mix of synchronous and asynchronous learning tools to provide the same quality education  their students expect. Instructors are using Mediasite lecture videos and real-time Zoom calls to continue teaching and learning and improve student outcomes.  

“Tools like Mediasite improve access to education for our students,” said Thomas Hoover, CIO, Louisiana Tech University. “We scaled up Mediasite campus-wide within one week in the spring. It will continue to be a great retention tool for students because we can create equity in the classroom and better outcomes for those who have difficulty working in a traditional class environment.”  

This fall, courses are taking place a variety of ways including face-to-face, online, and hybrid. Instructors create video lessons with Mediasite from their offices or homes for students to watch prior to class. Then, students meet in real-time via Zoom for small group collaboration.  

Creating a better learning experience for students with easy-to-use tech for instructors

A Mediasite user for nearly a decade, Louisiana Tech already had the infrastructure in place for success during the initial COVID-19 shutdown in the spring. But with less than 10 percent of its classes fully online at that time, the university needed to scale up quickly. Fast forward one week and 100 percent of classes were remote-ready, and a majority of Louisiana Tech’s faculty received training on how to use tools like Mediasite’s personal capture software.  

Mediasite video use doubled in the spring and summer compared to the prior term at the university – instructors created nearly 22,000 lesson videos alone during that period. To date, students have viewed these videos nearly 112,000 times, signaling that they’re relying on Mediasite as a valuable study tool.  

“We don’t know what’s going to happen in a month or two but having products like Mediasite is a tremendous help. Instructors can record lectures ahead of time or record a synchronous Zoom call and put it into Mediasite for students,” said Daniel Schales, Louisiana Tech’s Director for Infrastructure & IT. “This gives students the option to review the material as many times as they’d like.”  

Mediasite is central destination for university’s Zoom recordings

Louisiana Tech instructors can manage all their video content in one secure and searchable place in Mediasite. An integration with Mediasite and Zoom lets instructors decide what calls should be sent to Mediasite. The recordings are automatically uploaded into the appropriate course folder in Mediasite alongside their other valuable videos and then distributed to students directly in their learning management system.  

The Zoom recordings benefit from the full functionality of Mediasite – accessibility tools like closed captioning and transcription, robust search, video and caption editing, anytime and anywhere publishing, interactivity tools to track viewer engagement and back-end analytics.  

“Being able to automatically and easily bring our Zoom content to Mediasite will let our students access all the educational videos in one common interface,” said Darrell Eddy, IT Coordinator and Network Administrator. “Plus, they can search for keywords in the recorded Zoom files and Mediasite will pinpoint exact parts of the lecture.”  

“While this scenario certainly isn’t what students and instructors anticipated at the start of the year, Louisiana Tech University is fully embracing online learning as an opportunity to help its students learn with new technologies and communicate effectively with video. These are skills that students will continue to need throughout their educational and professional journeys,” said Joe Mozden Jr., CEO, Sonic Foundry, the maker of Mediasite. “Louisiana Tech is creating an engaging learning experience for students regardless of their location, and we are proud to continue our longstanding relationship with the university that is a quickly positioning itself as a leader in hybrid learning amid the pandemic.”  

Mediasite is a highly-automated and integrated video platform that facilitates hybrid learning in this new digital-first world. Trusted by 1,700 schools in 65 countries, Mediasite quickly and cost-effectively scales the capture, management, delivery and search of live and on-demand streaming videos. Mediasite’s solutions create the most engaging, data-rich and personalized learning experiences possible as students and instructors collaborate from a distance.    

About Louisiana Tech University

Louisiana Tech University offers students an unparalleled educational experience, and the University has been recognized as one of America’s Top Colleges in Forbes and as the No. 1 college in the state of Louisiana for value in Kiplinger’s. Located in Ruston, Louisiana, Tech has been ranked as a Top Tier research university in US News and World Report for 10 years, and is the only university in the state to be recognized in the Times Higher Education (THE) 2020 University Impact Rankings for its commitment to sustainable development. The University has a history of and commitment to creating programs that are the first in their fields, like biomedical and cyber engineering, and it is an economic driver for the region and state.  

About Sonic Foundry®, Inc.

Sonic Foundry (OTC: SOFO) is the global leader for video capture, management and streaming solutions. Trusted by more than 5,200 educational institutions, corporations, health organizations and government entities in over 65 countries, its Mediasite Video Platform quickly and cost-effectively automates the capture, management, delivery and search of live and on-demand streaming videos. Learn more at www.mediasite.com and @mediasite.

© 2020 Sonic Foundry, Inc. Product and service names mentioned herein are the trademarks of Sonic Foundry, Inc. or their respective owners.



Media Contact: Nicole Wise, Director of Communications
Sonic Foundry
920.226.0269
[email protected]

Harbor Custom Development, Inc. Projects $47 Million in 2020 Revenue and $70 Million in 2021

Gig Harbor, Washington , Nov. 23, 2020 (GLOBE NEWSWIRE) — Harbor Custom Development, Inc. (“Harbor,” “Harbor Custom Homes®,” or the “Company”), (NASDAQ:HCDI), an innovative and market leading real estate company involved in all aspects of the land development cycle, today announced that its 2020 gross revenues are projected to be $47 Million and that 2021 gross revenues are estimated at $70 Million.

Chief Executive Officer Sterling Griffin stated, “I am very proud of our management team and their ability to execute Harbor Custom Homes® stated business plan. Our extraordinary growth is a direct result of management’s focused efforts combined with favorable market conditions, including low interest rates, urban flight, and a growing work from home labor force. These projections are based on closed transactions and estimated revenue associated with currently owned, controlled or anticipated inventory in Washington State.”  

About Harbor Custom Development, Inc.

Harbor Custom Development, Inc., DBA Harbor Custom Homes®, is a real estate development company involved in all aspects of the land development cycle including land acquisition, entitlements, construction of project infrastructure, home building, marketing, sales, and management of various residential projects in Western Washington’s Puget Sound region.  Harbor has active or recently sold out residential communities in Gig Harbor, Bremerton, Silverdale, Bainbridge Island, and Allyn in the state of Washington.  Harbor Custom Development’s business strategy is to acquire and develop land strategically, based on an understanding of population growth patterns, entitlement restrictions, infrastructure development, and geo-economic forces.  Harbor focuses on real estate within target markets with convenient access to metropolitan areas that are generally characterized by diverse economic and employment bases and increasing populations.  For more information on Harbor Custom Development, Inc., please visit harborcustomhomes.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements relate to, but are not limited to, expectations of future operating results and financial performance, including GAAP and non-GAAP guidance for the year ending December 31, 2020 and the year ending December 31, 2021, the calculation of certain of our key financial and operating metrics and expectations regarding sales of inventory, as well as assumptions relating to the foregoing.  Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified.  In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “expect,” “plan,” anticipate,” “believe,” “estimate, “predict,” “target,” “project,” “intend,” “potential,” “would,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology that concern our expectations, strategy, priorities, plans, or intentions. You should not put undue reliance on any forward-looking statements.  Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all.  These forward-looking statements are subject to various risks and uncertainties, including without limitation  complications  due to COVID-19 which could cause delays in dates of completion or closings, and those risks and uncertainties set forth in the Company’s filings with the Securities and Exchange Commission.  Thus, actual results could be materially different.  This document includes statements of summarized financial projections.  There will be differences between the projected and actual results because events and circumstances frequently do not occur as expected and those differences may be material.  The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.



Investor Relations
Hanover International
[email protected]
866-744-0974

Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET

Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it will conduct a conference call with investors to review financial results for its third quarter ended September 30, 2020, and provide an update on clinical and corporate developments, including its advanced stage drug candidates Piclidenoson and Namodenoson.

Call Information

Date: Monday, November 30, 2020

Time: 9:15 a.m. ET

Dial-in U.S.: 1-877-423-9813

Dial-in Israel: 1-201-689-8573

Conference ID: 13713545

Audio Webcast: http://public.viavid.com/index.php?id=142533

A press release reviewing the third quarter results and clinical updates will be issued prior to the call. A replay of the webcast will be archived on Can-Fite’s website for a period of time.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company’s lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite’s liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact of the COVID-19 pandemic; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite’s filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Can-Fite BioPharma

Motti Farbstein

[email protected]

+972-3-9241114

KEYWORDS: Israel Middle East

INDUSTRY KEYWORDS: Medical Devices Health Technology Other Technology Software Biotechnology

MEDIA:

Logo
Logo